Understanding Herpes Simplex Infections Herpes Simplex Virus (HSV) is a common viral infection that leads to the formation of blisters and sores, typically around the mouth (oral herpes) or in the genital region (genital herpes). The condition is caused by two virus types: HSV-1 and HSV-2. While HSV can remain dormant in the body for extended periods, it may reactivate under specific triggers, causing recurrent outbreaks. Despite its high prevalence, there is still a considerable need for more effective antiviral therapies that can minimize outbreak frequency and improve patients’ quality of life. From prevalence to pipeline—our infographic breaks it down!: https://www.delveinsight.com/infographics/herpes-simplex-market?utm_source=infographics&utm_medium=promotion&utm_campaign=hpr Herpes Simplex Epidemiological Segmentation The epidemiological analysis of Herpes Simplex in the 7MM from 2020 to 2034 includes: Total seroprevalent cases of HSV Total symptomatic cases of HSV Total diagnosed cases of HSV Gender-specific diagnosed cases of HSV Total recurrent cases of HSV Herpes Simplex Epidemiology In 2023, Herpes Simplex prevalence showed distinct patterns across the 7MM: Around 13.04 million diagnosed cases of HSV were reported across the 7MM, with approximately 4.95 million cases in the United States. This number is projected to decline throughout the study period. Female-diagnosed cases were higher than male-diagnosed cases across the 7MM, with women comprising 55% of the total diagnosed population. In Japan, there were an estimated 1.56 million diagnosed cases of HSV in 2023—700,000 among males and 856,000 among females. These figures are also expected to decrease during the forecast period. Numbers tell part of the story—get the full analysis in our report: https://www.delveinsight.com/report-store/herpes-simplex-market?utm_source=infographics&utm_medium=promotion&utm_campaign=hpr Herpes Simplex Market In 2023, the total market size for Herpes Simplex in the 7MM was valued at approximately USD 3.1 billion. Herpes Simplex Market Drivers The advancement of novel antiviral therapies such as PRITELIVIR (AIC-316) and mRNA-1608 presents promising opportunities for improved HSV management and reduction in recurrence rates. Enhanced awareness and progress in diagnostic technologies are anticipated to facilitate better identification and treatment of symptomatic HSV cases, supporting market growth. Herpes Simplex Market Barriers The unpredictable nature of HSV outbreaks and variability in treatment response pose challenges to effective disease management and the development of standardized treatment protocols. Limited accessibility and high costs of novel antiviral agents may restrict their adoption, especially in low-resource settings, hindering broader market expansion. Herpes Simplex Emerging Therapies PRITELIVIR (AIC-316) GSK3943104 mRNA-1608 And others Herpes Simplex Key Players AiCuris Anti-infective Cures AG GlaxoSmithKline ModernaTX, Inc. And others Grab your free copy of the infographic—essential for any analyst!: https://www.delveinsight.com/infographics/herpes-simplex-market?utm_source=infographics&utm_medium=promotion&utm_campaign=hpr